Tag Archives: Solanezumab Trials

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Posted on November 23, 2016 by Dementia and Elderly Care News

Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Alzheimer’s and Dementia (Journal), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Avid Radiopharmaceuticals (Philadelphia), BBC Health News, Big Pharma, Clearance of Amyloid Beta Protein, Drug Trials, Drug Trials Failure Rate, Eli Lilly, Eli Lilly and Company (Indianapolis), EXPEDITION Studies, Intervention Trials, β-amyloid, LZAM, LZAN, Mild Alzheimer’s Disease, Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, United States, USA | Leave a comment

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Posted on July 22, 2015 by Dementia and Elderly Care News

Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Association International Conference (Washington, Alzheimer’s Association International Conference® (AAIC®) 2015, Alzheimer’s Research UK (ARUK), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, ARUK: Alzheimer’s Research UK, BBC Health News, Big Pharma, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Eli Lilly, EXPEDITION Studies, β-amyloid, July 2015), Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody | Leave a comment

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Posted on January 28, 2014 by Dementia and Elderly Care News

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading →

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged Alzheimer's Disease and Memory Disorders Center: Baylor College of Medicine (Houston), Alzheimer's Disease Assessment Scale (ADAS-Cog11), Alzheimer's Disease Cooperative Study Steering Committee, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), Alzheimer's Disease Cooperative Study: University of California at San Diego, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Baylor College of Medicine, Beta-Amyloid, Beta-Amyloid Plaques, Center for Human Experimental Therapeutics: University of Rochester Medical Center, Centre Hospitalier Universitaire Toulouse, Clinical Trials Number: NCT00904683, Clinical Trials Number: NCT00905372, Department of Neuropathology: University of Tokyo, Eli Lilly, Gerontopole: Unité Mixte de Recherche, Gliosis, Indiana Alzheimer Disease Center: Indiana University, Indiana University, β-amyloid, Neurofibrillary Tangles, Neuronal Loss, New England Journal of Medicine, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Study Group, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, University of California at San Diego, University of Pennsylvania, University of Rochester Medical Center | Leave a comment

Tag Archives: Solanezumab Trials

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites